Literature DB >> 19948090

beta-Adrenergic receptor blockers and heart failure risk after myocardial infarction: a critical review.

Robert H Neumayr1, Paul J Hauptman.   

Abstract

Remodeling after myocardial infarction is a complex biological process that leads to progressive left ventricular dilation and clinical heart failure. Multiple influences, including autonomic imbalance with sympathetic activation, contribute to the process. This article reviews clinical data in favor of early- and long-term use of beta-adrenergic receptor blockers in patients after myocardial infarction. Areas of uncertainty, such as the selection of dose and duration of therapy, current guidelines, and patterns of underuse of therapy with this important class of drugs are outlined and highlighted.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19948090     DOI： 10.1007/s11897-009-0031-7

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  68 in total

1.  Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction.

Authors:  Gunnar H Gislason; Jeppe N Rasmussen; Steen Z Abildstrøm; Niels Gadsbøll; Pernille Buch; Jens Friberg; Søren Rasmussen; Lars Køber; Steen Stender; Mette Madsen; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2006-01-06       Impact factor: 29.983

2.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Authors:  M A Pfeffer; G A Lamas; D E Vaughan; A F Parisi; E Braunwald
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

3.  Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure.

Authors:  B D Lowes; E A Gill; W T Abraham; J R Larrain; A D Robertson; M R Bristow; E M Gilbert
Journal:  Am J Cardiol       Date:  1999-04-15       Impact factor: 2.778

4.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.

Authors:  M A Konstam; M F Rousseau; M W Kronenberg; J E Udelson; J Melin; D Stewart; N Dolan; T R Edens; S Ahn; D Kinan
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

5.  Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience.

Authors:  R P Byington; J Worthy; T Craven; C D Furberg
Journal:  Am J Cardiol       Date:  1990-06-01       Impact factor: 2.778

Review 6.  The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening.

Authors:  Thomas J Wang; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Ann Intern Med       Date:  2003-06-03       Impact factor: 25.391

7.  Prognostic role of heart rate variability in patients with a recent acute myocardial infarction.

Authors:  G A Lanza; V Guido; M M Galeazzi; M Mustilli; R Natali; C Ierardi; C Milici; F Burzotta; V Pasceri; F Tomassini; A Lupi; A Maseri
Journal:  Am J Cardiol       Date:  1998-12-01       Impact factor: 2.778

8.  Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

Authors:  M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

10.  Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1986-07-12       Impact factor: 79.321
View more
  3 in total

1.  β-Blockers in coronary artery disease management.

Authors:  G E Boudonas
Journal:  Hippokratia       Date:  2010-10       Impact factor: 0.471

2.  Balancing influence between actors in healthcare decision making.

Authors:  Robert M Kaplan; Yair M Babad
Journal:  BMC Health Serv Res       Date:  2011-04-19       Impact factor: 2.655

3.  High N-terminal pro-B-type natriuretic peptide levels are associated with reduced heart rate variability in acute myocardial infarction.

Authors:  Luc Lorgis; Daniel Moreau; Laurent Mock; Bernadette Daumas; Daniel Potard; Claude Touzery; Yves Cottin; Marianne Zeller
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.